By Michael Susin

Royal Philips NV said Tuesday that its Capsule Surveillance technology has received market clearance from the U.S. Food & Drug Administration.

The Dutch health-technology company said that the clearance paves the way for deploying the solution across health systems in the U.S., and that it will start distributing it to limited sites in the second quarter.

The company's Capsule Surveillance is a technology that allows clinicians to remotely monitor large numbers of patients "from multiple device types without needing to enter the patient's room", it said.

Shares at 1219 GMT were down 0.28 euros, or 1.0%, at 28.33 euros.

Write to Michael Susin at michael.susin@wsj.com

(END) Dow Jones Newswires

March 15, 2022 08:42 ET (12:42 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Grafico Azioni Koninklijke Philips NV (EU:PHIA)
Storico
Da Mar 2024 a Apr 2024 Clicca qui per i Grafici di Koninklijke Philips NV
Grafico Azioni Koninklijke Philips NV (EU:PHIA)
Storico
Da Apr 2023 a Apr 2024 Clicca qui per i Grafici di Koninklijke Philips NV